Hepatitis B Viral Variants With Reduced Susceptibility To Nucleoside Analogs And Uses Thereof

Abstract

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.


Claims
Download PDF
Document Preview
Document History
  • Publication: Jun 29, 2010
  • Application: Sep 25, 2007
    US US 86072707 A
  • Priority: Sep 25, 2007
    US US 86072707 A
  • Priority: Jun 24, 2005
    US US 16600405 A
  • Priority: Oct 12, 2004
    US US 96333304 A
  • Priority: Apr 11, 2003
    AU AU 1932/003004 W
  • Priority: Jun 26, 2002
    AU AU PS322402 A
  • Priority: Apr 12, 2002
    AU AU PS171002 A

Download Citation


Sign in to the Lens

Feedback